Outset Medical, Inc. ( (OM) ) has released its Q4 earnings. Here is a breakdown of the information Outset Medical, Inc. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Outset Medical, Inc. is a medical technology company focused on revolutionizing dialysis with its Tablo Hemodialysis System, which simplifies the process and reduces costs across various care settings.
The company recently released its financial results for the fourth quarter and full year of 2024, showcasing a performance that exceeded prior guidance despite a challenging market environment. Outset Medical reported strong growth in recurring revenue and improvements in gross margin.
Key highlights from the earnings report include a fourth-quarter net revenue of $29.5 million, a modest increase compared to the previous quarter. The company achieved a gross margin of 36.5%, significantly up from the previous year, driven by its expanding Tablo installed base which grew by 10% in 2024. Recurring revenue from Tablo consumables and services played a crucial role, showing a year-over-year increase of 21%.
Despite facing a net loss of $25.6 million in the fourth quarter, Outset Medical managed to reduce its losses compared to the same period in 2023. Operating expenses were notably lower, reflecting the company’s efforts to streamline operations and focus on profitability. The company’s cash position remains strong, bolstered by recent financing activities.
Looking ahead, Outset Medical aims to continue its trajectory of growth and efficiency. The company provided a revenue guidance of $115 million to $125 million for 2025, with expectations to use significantly less cash compared to 2024. Management remains optimistic about maintaining momentum and driving meaningful growth in the coming year.
